Swiss National Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

Swiss National Bank’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-43,200	Closed	-$483K	–	2562
2023 Q3	$483K	Hold	43,200	–	–	﹤0.01%	2514
2023 Q2	$924K	Buy	43,200 +600	+1%	+$17.7K	﹤0.01%	2335
2023 Q1	$1.72M	Sell	42,600 -4,900	-10%	-$234K	﹤0.01%	1932
2022 Q4	$2.21M	Buy	47,500 +800	+2%	+$36.5K	﹤0.01%	1831
2022 Q3	$2.42M	Buy	46,700 +700	+2%	+$40.9K	﹤0.01%	1734
2022 Q2	$2.17M	Buy	46,000 +2,700	+6%	+$147K	﹤0.01%	1851
2022 Q1	$3.08M	Buy	43,300 +3,300	+8%	+$215K	﹤0.01%	1764
2021 Q4	$2.99M	Hold	40,000	–	–	﹤0.01%	1790
2021 Q3	$2.27M	Hold	40,000	–	–	﹤0.01%	1973
2021 Q2	$1.76M	Buy	40,000 +1,000	+3%	+$49K	﹤0.01%	2193
2021 Q1	$1.92M	Buy	39,000 +500	+1%	+$24.9K	﹤0.01%	2028
2020 Q4	$1.62M	Hold	38,500	–	–	﹤0.01%	2028
2020 Q3	$1.76M	Buy	38,500 +700	+2%	+$33.9K	﹤0.01%	1782
2020 Q2	$1.9M	Buy	37,800 +9,100	+32%	+$471K	﹤0.01%	1745
2020 Q1	$1.48M	Buy	28,700 +400	+1%	+$21.3K	﹤0.01%	1632
2019 Q4	$1.75M	Buy	28,300 +600	+2%	+$37.2K	﹤0.01%	1810
2019 Q3	$1.66M	Buy	27,700 +600	+2%	+$44.6K	﹤0.01%	1766
2019 Q2	$2.29M	Buy	27,100 +600	+2%	+$54K	﹤0.01%	1612
2019 Q1	$2.53M	Buy	26,500 +800	+3%	+$71.8K	﹤0.01%	1509
2018 Q4	$1.82M	Buy	25,700 +700	+3%	+$53.7K	﹤0.01%	1639
2018 Q3	$2.14M	Hold	25,000	–	–	﹤0.01%	1678
2018 Q2	$2.9M	Hold	25,000	–	–	﹤0.01%	1463
2018 Q1	$2.02M	Buy	25,000 +1,500	+6%	+$115K	﹤0.01%	1632
2017 Q4	$1.38M	Hold	23,500	–	–	﹤0.01%	1891
2017 Q3	$1.1M	Hold	23,500	–	–	﹤0.01%	2003
2017 Q2	$846K	Hold	23,500	–	–	﹤0.01%	2153
2017 Q1	$724K	Buy	23,500 +1,200	+5%	+$37.4K	﹤0.01%	2215
2016 Q4	$747K	Hold	22,300	–	–	﹤0.01%	2208
2016 Q3	$593K	Hold	22,300	–	–	﹤0.01%	2264
2016 Q2	$492K	Buy	22,300 +5,800	+35%	+$152K	﹤0.01%	2360
2016 Q1	$468K	Buy	16,500 +3,100	+23%	+$86.3K	﹤0.01%	2340
2015 Q4	$442K	Hold	13,400	–	–	﹤0.01%	2327
2015 Q3	$484K	Buy	13,400 +1,700	+15%	+$73K	﹤0.01%	2195
2015 Q2	$526K	Buy	11,700 +3,300	+39%	+$128K	﹤0.01%	2213
2015 Q1	$257K	Hold	8,400	–	–	﹤0.01%	2428
2014 Q4	$427K	Hold	8,400	–	–	﹤0.01%	2265
2014 Q3	$332K	Hold	8,400	–	–	﹤0.01%	2300
2014 Q2	$362K	Buy	8,400 +2,600	+45%	+$99.2K	﹤0.01%	2317
2014 Q1	$232K	Buy	5,800 +1,500	+35%	+$54.5K	﹤0.01%	2405
2013 Q4	$117K	Buy	+4,300	New	+$104K	﹤0.01%	2464

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Swiss National Bank's ENTA Position: Q4 2023 in Review

Swiss National Bank sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 43,200 shares — an estimated $483K sold.

Swiss National Bank first reported a position in ENTA in Q4 2013 and held it in 40 quarters. The position peaked at $3.08M in Q1 2022. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Swiss National Bank reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Swiss National Bank sold 43,200 Enanta Pharmaceuticals shares in Q4 2023, an estimated $483K.
Swiss National Bank first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 40 quarters.
Swiss National Bank's Enanta Pharmaceuticals position peaked at $3.08M in Q1 2022.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.